Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir

被引：42

作者：

Bernuth, Sebastian ^{[1
]}

Yagmur, Eray ^{[2
,3
]}

Schuppan, Detlef ^{[4
]}

Sprinzl, Martin F. ^{[1
]}

Zimmermann, Anca ^{[5
]}

Schad, Arno ^{[6
]}

Kittner, Jens M. ^{[1
]}

Weyer, Veronika ^{[7
]}

Knapstein, Johanna ^{[1
]}

Schattenberg, Joern M. ^{[1
]}

Woerns, Marcus A. ^{[1
]}

Galle, Peter R. ^{[1
]}

Zimmermann, Tim ^{[1
]}

机构：

[1] Johannes Gutenberg Univ Mainz, CCM, Dept Med 1, Langenbeckstr 1, D-55101 Mainz, Germany

[2] RWTH Univ Hosp Aachen, Lab Diagnost Ctr, Aachen, Germany

[3] Dr Stein & Colleagues, Med Care Ctr, Monchengladbach, Germany

[4] Univ Med Ctr Mainz, Inst Translat Immunol, Mainz, Germany

[5] Univ Med Ctr Mainz, Dept Endocrinol & Metab Dis, Mainz, Germany

[6] Johannes Gutenberg Univ Mainz, Inst Pathol, D-55101 Mainz, Germany

[7] Univ Med Ctr Mainz, IMBEI, Mainz, Germany

来源：

DIGESTIVE AND LIVER DISEASE | 2016年 / 48卷 / 03期

关键词：

ELF; FibroScan; Liver fibrosis; Liver stiffness measurement; Non-invasive serum markers; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT-NAIVE PATIENTS; TRANSIENT ELASTOGRAPHY; INSULIN-RESISTANCE; CLINICAL-OUTCOMES; SERUM FIBROSIS; HCV TREATMENT; GENOTYPE; RIBAVIRIN; CIRRHOSIS;

D O I：

10.1016/j.dld.2015.09.015

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

100201 [内科学];

摘要：

Background: Chronic hepatitis C is a major cause of liver-associated mortality caused by decompensated cirrhosis and hepatocellular carcinoma. With the approval of sofosbuvir, therapeutic efficacy has markedly increased. Early changes in non-invasive biomarkers of liver fibrosis under effective antiviral therapy are widely unknown. Aim: To evaluate early changes of fibrosis markers determined by enhanced liver fibrosis (ELF) scores and liver stiffness measurement (FibroScan (R)) in patients treated with sofosbuvir. Methods: A total of 32 hepatitis C patients treated prospectively with sofosbuvir were included. The ELF-panel and FibroScan measurements were performed at baseline, week 4, end-of-treatment and 12 weeks thereafter. Results: Antiviral therapy resulted in a biochemical and virological response within 4 weeks. Sustained virological response rate at 12-week follow-up (SVR12) was 93.8%; there was a significantly decrease from baseline to 12-week post-treatment follow-up in ELF (10.00 vs. 9.37; p = 0.007) and FibroScan (8.0 vs. 6.8 kPa; p = 0.016) measurements, indicating improvement of the dynamics of liver fibrosis. Conclusion: We observed a rapid decrease in non-invasive fibrosis markers measured by ELF-scores and FibroScan in hepatitis C-infected patients receiving sofosbuvir treatment. These initial results need to be histologically confirmed by liver biopsy in the future. (C) 2015 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

引用

页码：291 / 297

页数：7

共 43 条

[1]

Role of low-density lipoprotein receptor in the hepatitis C virus life cycle [J].